Your browser doesn't support javascript.
loading
The investigation of genetic and clinical features in Chinese patients with juvenile amyotrophic lateral sclerosis.
Liu, Z-J; Lin, H-X; Liu, G-L; Tao, Q-Q; Ni, W; Xiao, B-G; Wu, Z-Y.
Afiliación
  • Liu ZJ; Department of Neurology and Institute of Neurology, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
  • Lin HX; Department of Neurology and Research Center of Neurology in Second Affiliated Hospital, and The Collaborative Innovation Center for Brain Science, Zhejiang University School of Medicine, Hangzhou, China.
  • Liu GL; Department of Neurology and Institute of Neurology, First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
  • Tao QQ; Department of Neurology and Research Center of Neurology in Second Affiliated Hospital, and The Collaborative Innovation Center for Brain Science, Zhejiang University School of Medicine, Hangzhou, China.
  • Ni W; Department of Neurology and Research Center of Neurology in Second Affiliated Hospital, and The Collaborative Innovation Center for Brain Science, Zhejiang University School of Medicine, Hangzhou, China.
  • Xiao BG; Department of Neurology and Research Center of Neurology in Second Affiliated Hospital, and The Collaborative Innovation Center for Brain Science, Zhejiang University School of Medicine, Hangzhou, China.
  • Wu ZY; Department of Neurology and Institute of Neurology, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
Clin Genet ; 92(3): 267-273, 2017 Sep.
Article en En | MEDLINE | ID: mdl-28429524
ABSTRACT
Juvenile amyotrophic lateral sclerosis (JALS) occurs at an age of onset below 25 years with a heterogeneous disease onset location, variable progression and survival time. To investigate whether an ALS gene profile could resolve any aspects of clinical symptom heterogeneity, we have used targeted sequencing technology in a cohort of 12 JALS patients of Chinese descent. We detected 5 likely pathogenic mutations, 2 in familial probands and 3 in sporadic patients. One was a known TARDBP mutation (p.G348V) and 4 were FUS frameshift mutations including a known p.Gln519Ilefs*9 mutation and 3 novel mutations, p.Gly515Valfs*14, p.Gly486Profs*30, and p.Arg498Alafs*32. Of the 4 FUS mutations, 2 were able to be confirmed as de novo mutations. The TARDBP mutation carrier showed a classic ALS phenotype. All patients with FUS mutations experienced limb weakness at an early age and developed bulbar symptoms during the disease course. FUS mutations have previously been associated with increased JALS disease progression, however, we found a large range 12 to 84 months in disease survival (mean 58.2 months). Our results justify future screening for variants in FUS as it remains the most frequent genetic determinant of early onset, JALS (found in 30% of our patients).
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Predisposición Genética a la Enfermedad / Pueblo Asiatico / Estudios de Asociación Genética / Esclerosis Amiotrófica Lateral Tipo de estudio: Prognostic_studies Límite: Adolescent / Adult / Child / Female / Humans / Male País/Región como asunto: Asia Idioma: En Revista: Clin Genet Año: 2017 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Predisposición Genética a la Enfermedad / Pueblo Asiatico / Estudios de Asociación Genética / Esclerosis Amiotrófica Lateral Tipo de estudio: Prognostic_studies Límite: Adolescent / Adult / Child / Female / Humans / Male País/Región como asunto: Asia Idioma: En Revista: Clin Genet Año: 2017 Tipo del documento: Article País de afiliación: China